We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Urine Sediment Findings in Patients With COVID-19-Associated Renal Injuries

By LabMedica International staff writers
Posted on 11 Apr 2022

Patients with COVID-19 can suffer from renal complications, especially acute kidney injury (AKI). More...

AKI is a frequent complication in patients with critically severe COVID-19, and a meta-analysis report has shown that the average incidence of AKI was 11% among all subjects with COVID-19 and 23% among critically ill patients.

Urinalysis and urine sediment examinations are the oldest and most commonly performed tests for assessing the pathophysiological condition of the kidney/urethral system. Urinalysis findings such as proteinuria, hematuria, and leukocyturia are reportedly associated with COVID-19-associated renal injuries and the severity of COVID-19.

Clinical Laboratory Scientists at the University of Tokyo Hospital (Tokyo, Japan) collected residual urine samples from 88 subjects with COVID-19 (total: 279 samples; average: three samples per patient; range: 1–16 samples) diagnosed using RT-PCR. The also collected urine samples from 78 subjects (total: 147 samples; average: two samples per patient; range: 1–9 samples) with acute renal injuries caused by non-COVID-19 factors, who were admitted to an emergency or intensive care unit (ICU).

The urine sediment examination was performed using manual microscopy. For the measurement of urinary clinical markers, the team used the following reagents: urinary creatinine (uCr) was measured using an enzyme assay (L-type Wako CRE • M; FUJIFILM Wako Pure Chemical, Osaka, Japan); total protein (TP) (Micro TP-test Wako) was measured using the pyrogallol red method; microalbumin (µAlb) (Auto Wako microalbumin; FUJIFILM Wako) was measured using a turbidimetric immunoassay (TIA); N-acetyl-β-D-glucosaminidase (Ltype Wako NAG) was measured using an enzyme assay; α1-MG (LZtest ‘Eiken’ α1-M; Eiken Chemical, Tokyo, Japan) was measured using latex agglutination turbidimetry;

Liver type fatty acid-binding protein (L-FABP) (NORUDIA L-FABP; SEKISUI MEDICAL, Japan) was measured using latex agglutination turbidimetry; and NGAL (U-NGAL Abbott; Abbott Park, IL, USA) was measured using a chemiluminescence immunoassay (CLIA). Urinary specific gravity (SG) was measured using an Eiken Chemical automated urine chemical analyzer US-3500 and urinary sodium was measured using an electrode method.

The investigators reported that that the number of urine sediment particles and the levels of N-acetyl-β-D-glucosaminidase, α1-microglobulin, liver type fatty acid-binding protein, and neutrophil gelatinase-associated lipocalin were associated with the severity of COVID-19. In addition, they observed that the number of granular casts, epithelial casts, waxy casts, and urinary chemical marker levels were lower in the subjects with COVID-19 than subjects without COVID-19 with acute renal injuries when the subjects were classified according to their renal function.

The authors concluded that the urinary sediment findings were milder in subjects with COVID-19 when compared according to their renal functions, suggesting that pre-renal injury factors might be largely involved in the pathogenesis of COVID-19-associated renal injuries than non-COVID-19-associated renal injuries in patients with AKI arising from surgery or sepsis. The study was published on April 1, 2022 in the International Journal of Infectious Diseases.

Related Links:
University of Tokyo Hospital
FUJIFILM Wako Pure Chemical
SEKISUI MEDICAL
Abbott
Eiken Chemical
 


New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Immunoblots Processor
BlueDiver Instrument II
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.